100 related articles for article (PubMed ID: 19247089)
1. In arrayed ranks: array technology in the study of mesothelioma.
Gray SG; Fennell DA; Mutti L; O'Byrne KJ
J Thorac Oncol; 2009 Mar; 4(3):411-25. PubMed ID: 19247089
[TBL] [Abstract][Full Text] [Related]
2. Microdissection, mRNA amplification and microarray: a study of pleural mesothelial and malignant mesothelioma cells.
Mohr S; Bottin MC; Lannes B; Neuville A; Bellocq JP; Keith G; Rihn BH
Biochimie; 2004 Jan; 86(1):13-9. PubMed ID: 14987796
[TBL] [Abstract][Full Text] [Related]
3. Management of malignant pleural mesothelioma.
West SD; Lee YC
Clin Chest Med; 2006 Jun; 27(2):335-54. PubMed ID: 16716822
[TBL] [Abstract][Full Text] [Related]
4. Pleural-based mesothelioma in immune competent rats: a model to study adenoviral gene transfer.
Kucharczuk JC; Elshami AA; Zhang HB; Smythe WR; Hwang HC; Tomlinson JS; Amin KM; Litzky LA; Albelda SM; Kaiser LR
Ann Thorac Surg; 1995 Sep; 60(3):593-7; discussion 597-8. PubMed ID: 7677485
[TBL] [Abstract][Full Text] [Related]
5. Identification of novel candidate oncogenes and tumor suppressors in malignant pleural mesothelioma using large-scale transcriptional profiling.
Gordon GJ; Rockwell GN; Jensen RV; Rheinwald JG; Glickman JN; Aronson JP; Pottorf BJ; Nitz MD; Richards WG; Sugarbaker DJ; Bueno R
Am J Pathol; 2005 Jun; 166(6):1827-40. PubMed ID: 15920167
[TBL] [Abstract][Full Text] [Related]
6. Genome-wide profile of pleural mesothelioma versus parietal and visceral pleura: the emerging gene portrait of the mesothelioma phenotype.
Røe OD; Anderssen E; Helge E; Pettersen CH; Olsen KS; Sandeck H; Haaverstad R; Lundgren S; Larsson E
PLoS One; 2009 Aug; 4(8):e6554. PubMed ID: 19662092
[TBL] [Abstract][Full Text] [Related]
7. MicroRNAs dysregulation in human malignant pleural mesothelioma.
Balatti V; Maniero S; Ferracin M; Veronese A; Negrini M; Ferrocci G; Martini F; Tognon MG
J Thorac Oncol; 2011 May; 6(5):844-51. PubMed ID: 21358347
[TBL] [Abstract][Full Text] [Related]
8. Genetics of malignant pleural mesothelioma: molecular markers and biologic targets.
Bueno R; Gordon GJ
Thorac Surg Clin; 2004 Nov; 14(4):461-8. PubMed ID: 15559052
[TBL] [Abstract][Full Text] [Related]
9. Identification of potential therapeutic targets in malignant mesothelioma using cell-cycle gene expression analysis.
Romagnoli S; Fasoli E; Vaira V; Falleni M; Pellegrini C; Catania A; Roncalli M; Marchetti A; Santambrogio L; Coggi G; Bosari S
Am J Pathol; 2009 Mar; 174(3):762-70. PubMed ID: 19218339
[TBL] [Abstract][Full Text] [Related]
10. Transcriptional profiling of mesothelioma using microarrays.
Gordon GJ
Lung Cancer; 2005 Jul; 49 Suppl 1():S99-S103. PubMed ID: 15950812
[TBL] [Abstract][Full Text] [Related]
11. Validation of genomics-based prognostic tests in malignant pleural mesothelioma.
Gordon GJ; Rockwell GN; Godfrey PA; Jensen RV; Glickman JN; Yeap BY; Richards WG; Sugarbaker DJ; Bueno R
Clin Cancer Res; 2005 Jun; 11(12):4406-14. PubMed ID: 15958625
[TBL] [Abstract][Full Text] [Related]
12. [Gene expression profiling in human mesothelioma cells using DNA microarray and high-density filter array technologies].
Mohr S; Rihn B
Bull Cancer; 2001 Mar; 88(3):305-13. PubMed ID: 11313208
[TBL] [Abstract][Full Text] [Related]
13. Genomic events associated with progression of pleural malignant mesothelioma.
Ivanov SV; Miller J; Lucito R; Tang C; Ivanova AV; Pei J; Carbone M; Cruz C; Beck A; Webb C; Nonaka D; Testa JR; Pass HI
Int J Cancer; 2009 Feb; 124(3):589-99. PubMed ID: 18973227
[TBL] [Abstract][Full Text] [Related]
14. Tissue factor pathway inhibitor expression by human pleural mesothelial and mesothelioma cells.
Bajaj MS; Pendurthi U; Koenig K; Pueblitz S; Idell S
Eur Respir J; 2000 Jun; 15(6):1069-78. PubMed ID: 10885426
[TBL] [Abstract][Full Text] [Related]
15. A comparison of epidermal growth factor receptor expression in malignant peritoneal and pleural mesothelioma.
Enomoto Y; Kasai T; Takeda M; Takano M; Morita K; Kadota E; Iizuka N; Maruyama H; Haratake J; Kojima Y; Ikeda N; Nonomura A
Pathol Int; 2012 Apr; 62(4):226-31. PubMed ID: 22449226
[TBL] [Abstract][Full Text] [Related]
16. Activated leukocyte cell-adhesion molecule (ALCAM) promotes malignant phenotypes of malignant mesothelioma.
Ishiguro F; Murakami H; Mizuno T; Fujii M; Kondo Y; Usami N; Yokoi K; Osada H; Sekido Y
J Thorac Oncol; 2012 May; 7(5):890-9. PubMed ID: 22722789
[TBL] [Abstract][Full Text] [Related]
17. Gene expression profile of aquaporin 1 and associated interactors in malignant pleural mesothelioma.
Jagirdar R; Solenov EI; Hatzoglou C; Molyvdas PA; Gourgoulianis KI; Zarogiannis SG
Gene; 2013 Mar; 517(1):99-105. PubMed ID: 23313295
[TBL] [Abstract][Full Text] [Related]
18. Flow cytometric analysis of a localized malignant mesothelioma.
Gómez-Román JJ; Mons-Lera R; Olmedo IS; Val-Bernal JF
Ann Thorac Surg; 2002 Apr; 73(4):1292-4. PubMed ID: 11996274
[TBL] [Abstract][Full Text] [Related]
19. [Asbestos and malignant pleural mesothelioma: molecular, cellular and physiopathological aspects].
Mohr S; Keith G; Rihn B
Bull Cancer; 2005 Nov; 92(11):959-76. PubMed ID: 16316830
[TBL] [Abstract][Full Text] [Related]
20. Defective core-apoptosis signalling in diffuse malignant pleural mesothelioma: opportunities for effective drug development.
Fennell DA; Rudd RM
Lancet Oncol; 2004 Jun; 5(6):354-62. PubMed ID: 15172356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
